Mirum Pharmaceuticals, a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases, to acquire Bile Acid Product Portfolio from Travere Therapeutics, a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease, for $445m. “The addition of the bile acid replacement therapies from Travere will strengthen our pipeline and offer an opportunity to leverage our unique expertise in the development and commercialization of treatments in rare and underserved liver diseases. This synergistic acquisition of the bile acid portfolio along with the opportunity to sponsor the genetic testing program will help to reinforce our leadership position in pediatric hepatology. We look forward to building on the meaningful work initiated by the talented Travere team and delivering on our commitment to advancing research and bringing treatments to rare liver disease patients in need,” Chris Peetz, Mirum President and CEO.